NASDAQ : TRVI
Trevi Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 13.81 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.97B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 18.19M | 15.85M | 12.15M | 10.24M | 10.07M | 9.49M |
| Research & Development | 41.37M | 33.48M | 39.38M | 23.68M | 19.83M | 22.98M |
| Operating Expenses | 59.56M | 49.33M | 51.52M | 33.92M | 29.91M | 32.48M |
| Operating Income | -59.56M | -49.33M | -51.52M | -33.92M | -29.91M | -32.48M |
| Interest Expense | -4.00K | -391.00K | -1.16M | -1.20M | ||
| Interest & Investment Income | 8.40M | 6.54M | 3.60M | 4.75M | 1.74M | 10.00K |
| Other Non Operating Income (Expenses) | -31.00K | -31.00K | -15.00K | 469.00K | 142.00K | -293.00K |
| EBT Excluding Unusual Items | -51.18M | -42.82M | -47.94M | -29.10M | -29.19M | -33.96M |
| Pretax Income | -51.18M | -42.82M | -47.94M | -29.10M | -29.19M | -33.96M |
| Income Tax Expense | -71.00K | -64.00K | -30.00K | -32.00K | -36.00K | -21.00K |
| Net Income | -51.11M | -42.76M | -47.91M | -29.07M | -29.15M | -33.94M |
| Net Income to Common | -51.11M | -42.76M | -47.91M | -29.07M | -29.15M | -33.94M |
| Shares Outstanding (Basic) | 145.64M | 134.75M | 101.97M | 99.03M | 64.54M | 22.84M |
| Shares Outstanding (Diluted) | 145.64M | 134.75M | 101.97M | 99.03M | 64.54M | 22.84M |
| EPS (Basic) | -0.35 | -0.32 | -0.47 | -0.29 | -0.45 | -1.49 |
| EPS (Diluted) | -0.35 | -0.32 | -0.47 | -0.29 | -0.45 | -1.49 |
| Free Cash Flow | -52.87M | -42.10M | -38.29M | -31.85M | -28.33M | -28.95M |
| Free Cash Flow Per Share | -0.36 | -0.31 | -0.38 | -0.32 | -0.44 | -1.27 |
| EBITDA | -59.42M | -49.18M | -51.38M | -33.80M | -29.86M | -32.43M |
| D&A For EBITDA | 137.00K | 144.00K | 147.00K | 123.00K | 43.00K | 50.00K |
| EBIT | -59.56M | -49.33M | -51.52M | -33.92M | -29.91M | -32.48M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 54.30M | 18.91M | 34.10M | 32.40M | 12.59M | 36.83M |
| Short-Term Investments | 264.57M | 169.35M | 73.53M | 50.57M | 107.92M | |
| Cash & Short-Term Investments | 318.87M | 188.26M | 107.62M | 82.97M | 120.51M | 36.83M |
| Other Receivables | 1.60M | 986.00K | 532.00K | 485.00K | ||
| Receivables | 1.60M | 986.00K | 532.00K | 485.00K | ||
| Prepaid Expenses | 4.26M | 1.26M | 939.00K | 3.62M | 795.00K | 886.00K |
| Other Current Assets | 972.00K | 1.15M | 335.00K | 470.00K | 1.31M | 241.00K |
| Total Current Assets | 325.70M | 191.66M | 109.43M | 87.55M | 122.62M | 37.96M |
| Property, Plant & Equipment | 878.00K | 855.00K | 1.23M | 1.56M | 194.00K | 184.00K |
| Other Long-Term Assets | 3.94M | 928.00K | 243.00K | 297.00K | 205.00K | 334.00K |
| Total Assets | 330.52M | 193.44M | 110.90M | 89.40M | 123.02M | 38.48M |
| Accounts Payable | 3.10M | 3.91M | 3.41M | 1.81M | 2.86M | 2.85M |
| Accrued Expenses | 5.31M | 5.53M | 6.81M | 3.71M | 3.52M | 3.81M |
| Current Portion of Long-Term Debt | 7.00M | 5.95M | ||||
| Current Portion of Leases | 329.00K | 307.00K | 285.00K | 306.00K | 25.00K | 120.00K |
| Total Current Liabilities | 8.74M | 9.75M | 10.51M | 5.82M | 13.40M | 12.72M |
| Long-Term Debt | 2.15M | 8.65M | ||||
| Long-Term Leases | 276.00K | 446.00K | 747.00K | 1.03M | 2.00K | 24.00K |
| Other Long-Term Liabilities | 3.00K | |||||
| Total Liabilities | 9.01M | 10.20M | 11.26M | 6.86M | 15.56M | 21.40M |
| Common Stock | 142.00K | 128.00K | 94.00K | 68.00K | 60.00K | 29.00K |
| Additional Paid-In Capital | 682.58M | 512.77M | 386.53M | 321.64M | 317.59M | 197.96M |
| Retained Earnings | -360.79M | -329.80M | -287.05M | -239.13M | -210.07M | -180.92M |
| Comprehensive Income & Other | -425.00K | 148.00K | 61.00K | -29.00K | -122.00K | |
| Total Common Equity | 321.51M | 183.24M | 99.64M | 82.55M | 107.46M | 17.07M |
| Shareholders' Equity | 321.51M | 183.24M | 99.64M | 82.55M | 107.46M | 17.07M |
| Total Liabilities & Equity | 330.52M | 193.44M | 110.90M | 89.40M | 123.02M | 38.48M |
| Total Debt | 605.00K | 753.00K | 1.03M | 1.34M | 9.18M | 14.74M |
| Net Cash (Debt) | 318.26M | 187.51M | 106.59M | 81.63M | 111.33M | 22.09M |
| Net Cash Per Share | 2.19 | 1.39 | 1.05 | 0.82 | 1.72 | 0.97 |
| Filing Date Shares Outstanding | 142.48M | 128.40M | 96.68M | 68.96M | 60.05M | 30.81M |
| Total Common Shares Outstanding | 142.42M | 128.31M | 93.60M | 68.28M | 59.94M | 28.51M |
| Working Capital | 316.97M | 181.91M | 98.92M | 81.72M | 109.22M | 25.23M |
| Book Value Per Share | 2.26 | 1.43 | 1.06 | 1.21 | 1.79 | 0.60 |
| Tangible Book Value | 321.51M | 183.24M | 99.64M | 82.55M | 107.46M | 17.07M |
| Tangible Book Value Per Share | 2.26 | 1.43 | 1.06 | 1.21 | 1.79 | 0.60 |
| Machinery | 507.00K | 349.00K | 304.00K | 212.00K | 105.00K | |
| Construction In Progress | 1.00K | 7.00K | 17.00K | 53.00K | ||
| Leasehold Improvements | 29.00K | 29.00K | 29.00K | 130.00K | 130.00K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -51.11M | -42.76M | -47.91M | -29.07M | -29.15M | -33.94M |
| Depreciation & Amortization | 137.00K | 144.00K | 147.00K | 123.00K | 43.00K | 50.00K |
| Other Amortization | 26.00K | 26.00K | 570.00K | 520.00K | 599.00K | |
| Loss (Gain) From Sale of Assets | 7.00K | 7.00K | 10.00K | |||
| Loss (Gain) From Sale of Investments | -1.81M | -1.64M | -1.37M | -2.12M | -829.00K | |
| Stock-Based Compensation | 8.06M | 5.18M | 3.59M | 2.25M | 2.33M | 2.54M |
| Other Operating Activities | 422.00K | 437.00K | 460.00K | 377.00K | 147.00K | 293.00K |
| Change in Accounts Payable | -1.92M | -598.00K | 1.60M | -1.05M | 9.00K | 831.00K |
| Change in Other Net Operating Assets | -6.44M | -2.89M | 5.22M | -2.80M | -1.24M | 678.00K |
| Operating Cash Flow | -52.63M | -42.09M | -38.26M | -31.71M | -28.18M | -28.95M |
| Capital Expenditures | -238.00K | -12.00K | -35.00K | -137.00K | -159.00K | |
| Investment in Securities | -176.38M | -94.09M | -21.49M | 59.56M | -107.21M | |
| Investing Cash Flow | -176.62M | -94.11M | -21.53M | 59.43M | -107.37M | |
| Long-Term Debt Repaid | -11.00K | -126.00K | -9.50M | -5.83M | ||
| Net Debt Issued (Repaid) | -11.00K | -126.00K | -9.50M | -5.83M | ||
| Issuance of Common Stock | 166.43M | 121.11M | 61.61M | 1.85M | 117.43M | 21.23M |
| Other Financing Activities | 61.00K | -84.00K | -258.00K | -289.00K | -450.00K | |
| Financing Cash Flow | 166.49M | 121.01M | 61.48M | -7.91M | 111.31M | 20.77M |
| Net Cash Flow | -62.76M | -15.18M | 1.70M | 19.81M | -24.24M | -8.17M |
| Free Cash Flow | -52.87M | -42.10M | -38.29M | -31.85M | -28.33M | -28.95M |
| Free Cash Flow Per Share | -0.36 | -0.31 | -0.38 | -0.32 | -0.44 | -1.27 |
| Levered Free Cash Flow | -33.28M | -27.86M | -21.03M | -21.97M | -17.95M | -16.50M |
| Unlevered Free Cash Flow | -33.28M | -27.86M | -21.03M | -21.91M | -17.74M | -16.35M |
| Cash Interest Paid | 4.00K | 331.00K | 594.00K | 603.00K | ||
| Change in Working Capital | -8.36M | -3.49M | 6.83M | -3.85M | -1.23M | 1.51M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 1.92B | 1.61B | 368.19M | 85.57M | 115.65M | 20.22M |
| Enterprise Value | 1.61B | 1.41B | 303.81M | -1.89M | 909.28K | 5.57M |
| Last Close Price | 13.56 | 12.52 | 4.12 | 1.34 | 1.93 | 0.78 |
| PB Ratio | 6.01 | 8.76 | 3.69 | 1.04 | 1.08 | 1.18 |
| P/TBV Ratio | 5.98 | 8.76 | 3.69 | 1.04 | 1.08 | 1.18 |
| Debt / Equity Ratio | 0.00 | 0.00 | 0.01 | 0.02 | 0.09 | 0.86 |
| Net Debt / Equity Ratio | -0.99 | -1.02 | -1.07 | -0.99 | -1.04 | -1.29 |
| Net Debt / EBITDA Ratio | 5.36 | 3.81 | 2.08 | 2.42 | 3.73 | 0.68 |
| Net Debt / FCF Ratio | 6.02 | 4.45 | 2.78 | 2.56 | 3.93 | 0.76 |
| Quick Ratio | 36.68 | 19.41 | 10.29 | 14.33 | 8.99 | 2.90 |
| Current Ratio | 37.28 | 19.66 | 10.41 | 15.03 | 9.15 | 2.98 |
| Return on Equity (ROE) | -19.66% | -30.23% | -52.59% | -30.59% | -46.82% | -153.03% |
| Return on Assets (ROA) | -13.81% | -20.26% | -32.15% | -19.96% | -23.15% | -47.42% |
| Return on Capital Employed (ROCE) | -18.50% | -26.90% | -51.30% | -40.60% | -27.30% | -126.10% |
| Earnings Yield | -2.60% | -2.66% | -13.01% | -33.97% | -25.21% | -167.88% |
| FCF Yield | -2.75% | -2.62% | -10.40% | -37.22% | -24.50% | -143.18% |
| Buyback Yield / Dilution | -26.95% | -32.14% | -2.97% | -53.44% | -182.56% | -26.48% |